NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

Interesting. I eagerly await the phase II trial initiations. If partnering occurs for some trial arms, I think Mr. Smith's (and apparently Ready's and your) argument, that this will bring further validation for NWBO, is true, but I'd suggest Captain Oblivion's point, that it's important first to really determine where partnering is and is not needed, should not get lost amongst the glare of big pharma acceptance. That said, the phase II diverse cancer trial might be somewhat complex with different arms. My soapbox on the matter is that if some trial arms attempt an adjuvant protocol with checkpoint inhibitors, they try intratumoral (not infusion) administration. BMY is the first to try this independently with one of their CIs, so they might be more ready to form an intratumoral trial arm with NWBO. I also think Dr. Bosch is leaning toward a Direct/CI cocktail being introduced after tumor control, immune propagation/activation and PDL1 upregulation have a chance to occur -- perhaps at 6 to 8 weeks after independent DCVax-Direct therapy starts. LP also previously discussed the need to limit and focus any potential CI therapy partnership.